A Phase 2 interventional study of TAK-226 in Myelodysplastic Syndromes, sponsored by Takeda. Recruiting at 21 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Myelodysplastic Syndromes by Takeda — 4 open to participants now, 4 under way, 2 of them phase 3. Myelodysplastic Syndromes · Takeda.
Among the 13 studies in Myelodysplastic Syndromes by Takeda, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, and was the 12th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →4 of the 13 studies in Myelodysplastic Syndromes by Takeda are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Takeda · Sites in United States, Australia, Brazil and 23 more countries
Ages 18+
Takeda · Sites in United States, Australia, Czechia and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is close to the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 66 across the 12 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Myelodysplastic Syndromes by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of the study is to evaluate how TAK-226 improves symptoms of transfusion-dependent anemia in Japanese patients with lower-risk myelodysplastic syndromes.
The study consists of Screening Period (up to 6 weeks), Treatment Period, Safety Follow-Up Period (8 weeks), and Long-Term Follow-Up Period (approximately 5 years from the first dose of the study treatment).
Participants of this study will be administered TAK-226 during Treatment Period. Subsequently, the participants will be monitored for side effects related to the study treatment during Safety Follow-Up Period and Long-Term Follow-Up Period. The approximate duration of participation for a participant is up to approximately 6 years.
During the study period, participants will visit the study clinic/hospital multiple times as per the study schedule. During Treatment Period, the participants will come to the clinic/hospital approximately every two to four weeks.
The criteria were revised on the registry on Oct 13, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of MDS with or without ring sideroblasts (RS) (as determined in an evaluable bone marrow sample collected at screening to confirm diagnosis) according to WHO 2016 classification that meets the International Prognostic Scoring System-Revised (IPSS-R) classification of very low-, low-, or intermediate-risk MDS.
Note: Due to expected impacts of transfusion, (Hgb) values from blood samples collected within 14 days following a red blood cell (RBC) transfusion and count obtained within 7 days following a platelet transfusion cannot be used for IPSS-R eligibility, unless considered pretransfusion values.
Transfusion dependent (TD) cohort: Transfusion dependence assessed in the 16 weeks immediately preceding enrollment in two 8-week blocks classified as either:
i. Only transfusion events for a pretransfusion Hgb \<10 grams per deciliter (g/dL) are counted toward eligibility; ii. At least 1 transfusion event in each 8-week block and a minimum of 2 transfusion events separated by >=7 days within the 16-week period immediately preceding enrollment; and iii. No consecutive 56-day period can be RBC transfusion-free during the 16 week period immediately preceding enrollment.
Note: Only transfusions for the disease under study will be counted towards classification for LTB or HTB participants. Transfusions for intercurrent diseases (bleeding, surgical procedure, infection, etc.) are not considered.
Non-transfusion dependent (NTD) cohort: NTD, defined as 0 to 1 RBC units per 8 weeks immediately preceding enrollment.
Note: RBC transfusions administered when Hgb levels were \<9.0 g/dL are counted for eligibility. RBC transfusions administered for other than MDS-related anemia (bleeding, surgical procedure, infection, etc.) will not be counted as a required transfusion for the purpose of meeting eligibility criteria.
TD cohort: or intolerant to prior erythropoiesis-stimulating agent (ESA) treatment (discontinued >=4 weeks before enrollment), or unlikely to respond to ESA treatment, defined as follows:
a. Refractory to prior ESA treatment: documentation of nonresponse or a response that was no longer maintained with a prior ESA-containing regimen, either as a single agent or combination (eg, with granulocyte colony-stimulating factor [G-CSF]); ESA regimen must have been either: i. Recombinant human erythropoietin (EPO) >=30,000 IU/week for >=8 doses or equivalent; or ii. Darbepoetin alpha >=500 mcrg every 3 weeks for >=3 doses, >=120 mcrg every week for >=8 doses or equivalent.
b. Intolerant to prior ESA treatment: documentation of discontinuation of a prior ESA containing regimen, either as a single agent or combination (eg, with G-CSF), at any time after introduction due to intolerance or an AE.
c. Unlikely to respond to ESA treatment: low chance of response to ESA based on an endogenous serum EPO level >200 U/L.
Note: Due to expected impacts of transfusion on EPO levels, blood samples collected within the 14 days following an RBC transfusion or within 7 days following a platelet transfusion cannot be used to evaluate serum EPO level for eligibility, unless considered pretransfusion values.
NTD cohort: Hgb \<10 g/dL and exhibiting anemia-related clinical symptoms (eg, fatigue, shortness of breath, or others) during screening.
Women of (WOCBP), defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally for at least 12 consecutive months must
Exclusion Criteria:
Medical History
cardiovascular disease defined as:
Prior history of , other than MDS, unless the participant has been free of the disease (including completion of any treatment, including maintenance, for prior malignancy) for >=2 years. However, participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy:
History of allergy/anaphylaxis to medicinal product (IMP) (refer to the current elritercept [TAK 226] IB for a list of excipients) or recombinant proteins.
Treatment History
TD cohort: Prior use of TAK 226, luspatercept, imetelstat, or sotatercept. NTD cohort: Prior use of TAK 226, luspatercept, imetelstat, sotatercept, or ESAs.
Note for NTD cohort: At the investigator's discretion in consultation with the medical monitor, may be allowed if received no more than 2 doses of ESAs >=8 weeks prior to enrollment.
Ongoing participation in another interventional clinical study.
Laboratory Exclusions (during Screening)
Estimated \<30 mL/min/1.73 m\^2 as determined by Japanese Society of Nephrology. Calculated by the correction formula for Japanese. a)
a) eGFR=194* (serum creatinine value)\^-1.094* (age)\^-0.287* (sex correction factor), Sex correction factor: 0.739 in female.
Miscellaneous
Investigational site staff members directly involved in the conduct of the study and site staff members otherwise supervised by the investigator, employees of the Sponsor or contract research organization (CRO) directly involved in the conduct of the study, or immediate family members (defined as a spouse, parent, child, or sibling, whether biological or legally adopted).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive the study drug, TAK-226, administered subcutaneously every four weeks (Q4W) for approximately one year during Treatment Period.
Drug: TAK-226
TAK-226 subcutaneous injection
Also known as: Elritercept, KER-050
Transfusion dependent (TD) cohort: Percentage of Participants Achieving Transfusion Independence (TI) for Greater Than or Equal to (>=) 8 Weeks from Baseline through Week 24
Transfusion independence is defined as the absence of any red blood cells (RBC) transfusions in a period of at least 8 weeks after the first dose of the study treatment through week 24.
Time frame: Baseline, Up to Week 24
Non-transfusion dependent (NTD) cohort: Percentage of Participants Achieving Mean Hgb Increase of >=1.5 grams per deciliter (g/dL) for >=8 Weeks from Baseline through Week 24 And No RBC Transfusion during the Same >=8 Weeks Period
Time frame: Baseline, Up to Week 24
TD cohort: Percentage of Participants Achieving TI for >=24 Weeks from Baseline through Week 48
Transfusion independence is defined as the absence of any red blood cells (RBC) transfusions in a period of at least 24 weeks after the first dose of the study treatment through week 48.
Time frame: Baseline, Up to Week 48
TD cohort: Percentage of Participants with High Transfusion Burden (HTB) Achieving TI for >=8 Weeks from Baseline through Week 24
Transfusion independence is defined as the absence of any RBC transfusions in a period of at least 8 weeks after the first dose of the study treatment through week 24.
Time frame: Baseline, Up to Week 24
TD cohort: Percentage of Participants Achieving Mean Hemoglobin (Hgb) Increase of >=1.5 g/dL for >=8 Weeks from Baseline through Week 24
Time frame: Baseline, Up to Week 24
TD cohort: Number of Participants with Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Event (SAEs)
An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of the trial intervention, whether or not the occurrence is considered related to the trial intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the trial intervention. A TEAE is defined as an AE that commences on or after the first dose of the study treatment and within 60 days after the last dose of the study treatment, or analysis cutoff date, whichever is earlier. An SAE is any untoward medical occurrence that, at any dose: results in death, is life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.
Time frame: Up to approximately 6 years
TD cohort: Serum Concentration of TAK-226
TAK-226 time-concentration data will be assessed.
Time frame: Baseline, and multiple time points up to the end of Treatment Period (approximately 12 months)
TD cohort: Number of Participants with Treatment-Emergent Anti-Drug Antibody (ADA)
Time frame: Up to the end of Safety Follow-Up Period (approximately 14 months)
TD cohort: ADA Titer
Time frame: Baseline, and multiple time points up to approximately 24 months
NTD cohort: Percentage of Participants Achieving Mean Hgb Increase of >=1.5 g/dL for >=12 Weeks from Baseline through Week 24 And No RBC Transfusion during the Same >=12 Weeks Period
Time frame: Baseline, Up to Week 24
NTD cohort: Percentage of Participants Achieving Consecutive Hgb Increase of >=1.5 g/dL for >=8 Weeks from Baseline through Week 24 And No RBC Transfusion during the Same >=8 Weeks Period
Time frame: Baseline, Up to Week 24
NTD cohort: Percentage of Participants Achieving Mean Hgb Increase of >=1.5 g/dL for >=16 Weeks from Baseline through Week 24 And through Week 48, And No RBC Transfusion during the Same >=16 Weeks Period
Time frame: Baseline, Up to Week 24 and Week 48
NTD cohort: Number of Participants with TEAEs and SAEs
Time frame: Up to approximately 6 years
TD and NTD cohorts: Change from baseline in Hematocrit
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Hemoglobin
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Red Cell Distribution Width
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Red Blood Cell
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Reticulocyte
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Platelet
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in White Blood Cell
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Neutrophils
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Eosinophils
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Basophils
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Lymphocytes
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Monocytes
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Mean Corpuscular Volume
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Mean Corpuscular Hemoglobin
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Mean Cell Hemoglobin Concentration
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Albumin
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Total Protein
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Blood Glucose
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Sodium
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Potassium
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Chloride
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Blood Urea Nitrogen
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Creatinine
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Aspartate Aminotransferase
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Alanine Aminotransferase
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Alkaline Phosphatase
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Gamma Glutamyl Transferase
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Total Bilirubin
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Lactate Dehydrogenase
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Calcium
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Magnesium
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Phosphorus
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Uric Acid
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Erythropoietin
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Thrombopoietin
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in N-Terminal Prohormone of Brain Natriuretic Protein
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Serum Iron
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Ferritin
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Transferrin
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Transferrin Saturation
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Total Iron Binding Capacity
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Soluble Transferrin Receptor
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Hepcidin
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Blood Pressure
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Heart Rate
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Respiratory Rate
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in Body Temperature
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in PR Interval
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in QRS Duration
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in QT Interval
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
TD and NTD cohorts: Change from baseline in QTcF Interval
Time frame: From the time of signing the informed consent form through safety follow-up, approximately 16 months
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.
Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 26 months is below that.
Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elritercept